Ambien (zolpidem) 10mg cannot be accessed through secure residential access points without a valid EPCS prescription from a DEA-registered US healthcare provider, as it is a Schedule IV controlled substance for short-term insomnia treatment only; unauthorized residential delivery constitutes federal felony distribution under 21 U.S.C. § 841 with up to 20-year imprisonment penalties.​
The 10mg dose serves men with ≥7-8 hours sleep opportunity (5mg preferred for women/elderly), maximum single nightly administration under 2025 FDA guidelines—no residential access circumvents synchronous HIPAA video ISI ≥15 confirmation, PDMP clearance, or post-December 31, 2025 in-person exam mandates across 50 states.​
Zolpidem tartrate 10mg (Ki 25nM), Tmax 1.6h, t½ 2.5h CYP3A4; black box complex sleep behaviors 1-5% (sleep-driving), next-morning impairment OR4 women, dependence 15-25% >4 weeks—discontinue parasomnias, taper 1.25-2.5mg weekly; contraindicated severe hepatic impairment, OSA AHI>15.​
Diagnostic: Insomnia Severity Index ≥15 + 3-month sleep diary.
Screening: PDMP clean 12mo, Epworth ≤10, UDS negative CNS depressants.
EPCS: #30 tabs 10mg zero refills 30 days signature pharmacy delivery.
Monitoring: ≥30% sleep latency q14d + UDS/pill counts.​
| Incidence | Effect Cluster | Risk Factors | Management ​ |
|---|---|---|---|
| 20-40% | Next-day RT>20% impairment | Women 10mg CYP3A4i | 5mg ≥8h no driving |
| 10-25% | Sleep-driving/eating | Alcohol co-ingestion | Immediate discontinuation |
| 5-15% | Amnesia >30min | >2 weeks | CBT-I substitution |
| 1-10% | Falls elderly | >65yo | 5mg bed alarms |
| <1% | Respiratory RR<12 | Opioids | Naloxone standby ​ |
Secure residential access point violates CSA Schedule IV distribution (21 CFR 1306.04), Ryan Haight post-flex in-person (21 USC 802(54))—federal felony per transaction.​
| Supporters | |||
| Name | Date | Amount | Comments |
| Total | $0.00 | ||